• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. Dec 1996; 64(12): 4952–4959.
PMCID: PMC174474

Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes.

Abstract

The mechanism by which Burkholderia pseudomallei is resistant to lysis by human serum is unknown but may include interference with complement activation, effective opsonization, or complement-mediated lysis. We investigated the interaction of B. pseudomallei with complement in the presence and absence of specific antibody to determine potential mechanisms of serum resistance. We demonstrated rapid activation and consumption of complement by B. pseudomallei which, in the absence of specific antibody, occurred predominantly via the alternative pathway. Complement activation was associated with deposition of the opsonically active C3b and iC3b fragments on the bacterial surface. C5b-9, detected on the bacterial surface after opsonic periods of 1 to 60 min, was susceptible to elution by 1 M NaCl, indicating that resistance to complement-mediated lysis may result from deposition of the membrane attack complex in a nonmicrobicidal location. To define the role of opsonins, we investigated the ability of polymorphonuclear leukocytes (PMNL) to phagocytose B. pseudomallei. Phagocytosis of bacteria by PMNL, and the observed oxidative response, was significantly increased by opsonization of organisms with complement and/or specific antibody. Despite opsonophagocytosis by PMNL and the production of an oxidative response, no significant bacterial killing was observed.

Full Text

The Full Text of this article is available as a PDF (310K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ashdown LR. Identification of Pseudomonas pseudomallei in the clinical laboratory. J Clin Pathol. 1979 May;32(5):500–504. [PMC free article] [PubMed]
  • Ashdown LR. An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology. 1979 Apr;11(2):293–297. [PubMed]
  • Ashdown LR, Guard RW. The prevalence of human melioidosis in Northern Queensland. Am J Trop Med Hyg. 1984 May;33(3):474–478. [PubMed]
  • Ashdown LR, Johnson RW, Koehler JM, Cooney CA. Enzyme-linked immunosorbent assay for the diagnosis of clinical and subclinical melioidosis. J Infect Dis. 1989 Aug;160(2):253–260. [PubMed]
  • Chaowagul W, Suputtamongkol Y, Dance DA, Rajchanuvong A, Pattara-arechachai J, White NJ. Relapse in melioidosis: incidence and risk factors. J Infect Dis. 1993 Nov;168(5):1181–1185. [PubMed]
  • Dance DA. Melioidosis: the tip of the iceberg? Clin Microbiol Rev. 1991 Jan;4(1):52–60. [PMC free article] [PubMed]
  • DANNENBERG AM, Jr, SCOTT EM. Melioidosis: pathogenesis and immunity in mice and hamsters. I. Studies with virulent strains of Malleomyces pseudomallei. J Exp Med. 1958 Jan 1;107(1):153–166. [PMC free article] [PubMed]
  • Desmarchelier PM, Dance DA, Chaowagul W, Suputtamongkol Y, White NJ, Pitt TL. Relationships among Pseudomonas pseudomallei isolates from patients with recurrent melioidosis. J Clin Microbiol. 1993 Jun;31(6):1592–1596. [PMC free article] [PubMed]
  • Drevets DA, Campbell PA. Roles of complement and complement receptor type 3 in phagocytosis of Listeria monocytogenes by inflammatory mouse peritoneal macrophages. Infect Immun. 1991 Aug;59(8):2645–2652. [PMC free article] [PubMed]
  • Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. 1980 Jul 1;152(1):20–30. [PMC free article] [PubMed]
  • Gordon DL, Johnson GM, Hostetter MK. Ligand-receptor interactions in the phagocytosis of virulent Streptococcus pneumoniae by polymorphonuclear leukocytes. J Infect Dis. 1986 Oct;154(4):619–626. [PubMed]
  • Gordon DL, Rice J, Finlay-Jones JJ, McDonald PJ, Hostetter MK. Analysis of C3 deposition and degradation on bacterial surfaces after opsonization. J Infect Dis. 1988 Apr;157(4):697–704. [PubMed]
  • Hall BF, Joiner KA. Strategies of obligate intracellular parasites for evading host defences. Immunol Today. 1991 Mar;12(3):A22–A27. [PubMed]
  • Heffernan EJ, Reed S, Hackett J, Fierer J, Roudier C, Guiney D. Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck. J Clin Invest. 1992 Sep;90(3):953–964. [PMC free article] [PubMed]
  • Ismail G, Razak N, Mohamed R, Embi N, Omar O. Resistance of Pseudomonas pseudomallei to normal human serum bactericidal action. Microbiol Immunol. 1988;32(7):645–652. [PubMed]
  • Joiner KA. Complement evasion by bacteria and parasites. Annu Rev Microbiol. 1988;42:201–230. [PubMed]
  • Joiner KA, Brown EJ, Frank MM. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol. 1984;2:461–491. [PubMed]
  • Joiner KA, Grossman N, Schmetz M, Leive L. C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo. J Immunol. 1986 Jan;136(2):710–715. [PubMed]
  • Joiner KA, Hammer CH, Brown EJ, Cole RJ, Frank MM. Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death. J Exp Med. 1982 Mar 1;155(3):797–808. [PMC free article] [PubMed]
  • Joiner KA, Hammer CH, Brown EJ, Frank MM. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane. J Exp Med. 1982 Mar 1;155(3):809–819. [PMC free article] [PubMed]
  • Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei. Infect Immun. 1996 Mar;64(3):782–790. [PMC free article] [PubMed]
  • Law SK, Lichtenberg NA, Levine RP. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol. 1979 Sep;123(3):1388–1394. [PubMed]
  • Leelarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis. 1989 May-Jun;11(3):413–425. [PubMed]
  • Mays EE, Ricketts EA. Melioidosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest. 1975 Aug;68(2):261–263. [PubMed]
  • Merino S, Albertí S, Tomás JM. Aeromonas salmonicida resistance to complement-mediated killing. Infect Immun. 1994 Dec;62(12):5483–5490. [PMC free article] [PubMed]
  • Moulder JW. Comparative biology of intracellular parasitism. Microbiol Rev. 1985 Sep;49(3):298–337. [PMC free article] [PubMed]
  • Nelson B, Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol. 1979 May;122(5):1994–1999. [PubMed]
  • Payne NR, Horwitz MA. Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors. J Exp Med. 1987 Nov 1;166(5):1377–1389. [PMC free article] [PubMed]
  • Piggott JA, Hochholzer L. Human melioidosis. A histopathologic study of acute and chronic melioidosis. Arch Pathol. 1970 Aug;90(2):101–111. [PubMed]
  • Pilz D, Vocke T, Heesemann J, Brade V. Mechanism of YadA-mediated serum resistance of Yersinia enterocolitica serotype O3. Infect Immun. 1992 Jan;60(1):189–195. [PMC free article] [PubMed]
  • Pramoonjago P, Kaneko M, Kinoshita T, Ohtsubo E, Takeda J, Hong KS, Inagi R, Inoue K. Role of TraT protein, an anticomplementary protein produced in Escherichia coli by R100 factor, in serum resistance. J Immunol. 1992 Feb 1;148(3):827–836. [PubMed]
  • Pruksachartvuthi S, Aswapokee N, Thankerngpol K. Survival of Pseudomonas pseudomallei in human phagocytes. J Med Microbiol. 1990 Feb;31(2):109–114. [PubMed]
  • Schiller NL, Joiner KA. Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun. 1986 Dec;54(3):689–694. [PMC free article] [PubMed]
  • Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol. 1990 Apr 1;144(7):2771–2780. [PubMed]
  • Schlesinger LS, Horwitz MA. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. J Clin Invest. 1990 Apr;85(4):1304–1314. [PMC free article] [PubMed]
  • Verhoef J, Peterson PK, Quie PG. Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria. J Immunol Methods. 1977;14(3-4):303–311. [PubMed]
  • White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet. 1989 Sep 23;2(8665):697–701. [PubMed]
  • Wong KT, Puthucheary SD, Vadivelu J. The histopathology of human melioidosis. Histopathology. 1995 Jan;26(1):51–55. [PubMed]
  • Woods DE, Jones AL, Hill PJ. Interaction of insulin with Pseudomonas pseudomallei. Infect Immun. 1993 Oct;61(10):4045–4050. [PMC free article] [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...